financetom
Business
financetom
/
Business
/
Cerence Product Chief Adds Chief Technology Officer Title; Fiscal Q3 Outlook Affirmed
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Cerence Product Chief Adds Chief Technology Officer Title; Fiscal Q3 Outlook Affirmed
Jul 2, 2024 3:27 PM

06:02 PM EDT, 07/02/2024 (MT Newswires) -- Cerence ( CRNC ) said late Tuesday it has appointed Chief Product Officer Nils Schanz to the additional role of chief technology officer, succeeding Iqbal Arshad, who will depart, effective Friday.

The company also reaffirmed its Q3 guidance, including for revenue of $66 million to $72 million.

Analysts polled by Capital IQ expect $68.5 million.

Cerence ( CRNC ) shares were down about 1.9% in after-hours activity.

Price: 3.0500, Change: -0.06, Percent Change: -1.93

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Sinovac Biotech Starts Enrolment in Late-Stage Trial of Investigational Bivalent Vaccine for HFMD
Sinovac Biotech Starts Enrolment in Late-Stage Trial of Investigational Bivalent Vaccine for HFMD
Dec 16, 2024
09:21 AM EST, 12/16/2024 (MT Newswires) -- Sinovac Biotech ( SVA ) said Monday that it has begun enrollment in a late-stage study of its investigational bivalent vaccine targeting Hand, Foot, and Mouth Disease, or HFMD, caused by enterovirus 71 and coxsackievirus 16. The company said the trial will evaluate the potential vaccine's efficacy, safety, and immune response in children...
GSK's Jemperli Recommended for Expanded Approval in Endometrial Cancer, Receives Breakthrough Therapy Designation for Rectal Cancer
GSK's Jemperli Recommended for Expanded Approval in Endometrial Cancer, Receives Breakthrough Therapy Designation for Rectal Cancer
Dec 16, 2024
09:21 AM EST, 12/16/2024 (MT Newswires) -- GSK (GSK) said Monday that the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended expanding the approval of its experimental drug, Jemperli, in combination with chemotherapy, as a first-line treatment for adults with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy. The company said the...
Larimar Therapeutics Says Early Data From Friedreich's Ataxia Study Suggest Better Clinical Outcomes
Larimar Therapeutics Says Early Data From Friedreich's Ataxia Study Suggest Better Clinical Outcomes
Dec 16, 2024
09:20 AM EST, 12/16/2024 (MT Newswires) -- Larimar Therapeutics ( LRMR ) said Monday that initial data from its ongoing long-term study of its experimental therapy nomlabofusp in patients with Friedreich's ataxia leaned toward improved clinical outcomes at day 90. The company said patients treated with daily injections of nomlabofusp saw tissue frataxin levels increase, supporting the drug's potential in...
Tamarack Valley Energy Declares Monthly Dividend
Tamarack Valley Energy Declares Monthly Dividend
Dec 16, 2024
09:15 AM EST, 12/16/2024 (MT Newswires) -- Tamarack Valley Energy ( TNEYF ) on Monday declared a monthly cash dividend on its common shares of $0.01275 per share, same as the prior month. The dividend will be payable on Jan. 15 to shareholders of record at the close of business on Dec. 30. Shares of the company closed down $0.03...
Copyright 2023-2026 - www.financetom.com All Rights Reserved